- Home
- BYSI vs CTSO Comparison
BYSI vs CTSO Comparison
Compare BYSI & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- CTSO
- Stock Information
- Founded
- BYSI 2010
- CTSO 1997
- Country
- BYSI United States
- CTSO United States
- Employees
- BYSI N/A
- CTSO N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- BYSI Health Care
- CTSO Health Care
- Exchange
- BYSI Nasdaq
- CTSO Nasdaq
- Market Cap
- BYSI 72.1M
- CTSO 61.3M
- IPO Year
- BYSI 2017
- CTSO N/A
- Fundamental
- Price
- BYSI $1.63
- CTSO $1.05
- Analyst Decision
- BYSI
- CTSO Strong Buy
- Analyst Count
- BYSI 0
- CTSO 3
- Target Price
- BYSI N/A
- CTSO $4.67
- AVG Volume (30 Days)
- BYSI 14.1K
- CTSO 85.6K
- Earning Date
- BYSI 01-01-0001
- CTSO 05-08-2025
- Dividend Yield
- BYSI N/A
- CTSO N/A
- EPS Growth
- BYSI N/A
- CTSO N/A
- EPS
- BYSI N/A
- CTSO N/A
- Revenue
- BYSI N/A
- CTSO $37,739,531.00
- Revenue This Year
- BYSI N/A
- CTSO $9.20
- Revenue Next Year
- BYSI N/A
- CTSO $11.64
- P/E Ratio
- BYSI N/A
- CTSO N/A
- Revenue Growth
- BYSI N/A
- CTSO 1.80
- 52 Week Low
- BYSI $1.37
- CTSO $0.70
- 52 Week High
- BYSI $3.63
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- BYSI 33.14
- CTSO 44.01
- Support Level
- BYSI $1.37
- CTSO $0.97
- Resistance Level
- BYSI $1.48
- CTSO $1.08
- Average True Range (ATR)
- BYSI 0.11
- CTSO 0.07
- MACD
- BYSI -0.02
- CTSO -0.01
- Stochastic Oscillator
- BYSI 19.15
- CTSO 17.53
Stock Price Comparison Chart: BYSI vs CTSO
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.